TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory H1 Antihistamines Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* persistent allergic rhinitis~Exclusion Criteria:~* the presence of asthma or nasal polyps,~* acute and chronic upper respiratory infections,~* administration of intranasal or systemic corticosteroids or H1 antihistamines in the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- healthy volunteers (Type: NO_INTERVENTION): healthy volunteers
- Desloratadine (Type: ACTIVE_COMPARATOR): patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
- Levocetirizine (Type: ACTIVE_COMPARATOR): patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies for monotherapy cohort.~* Patients with AML or High-Risk MDS who are newly diagnosed and previously untreated for combination cohort.~* Patients with AML who are newly diagnosed and previously untreated for azacitidine combination cohort.~* ECOG \[Eastern Cooperative Oncology Group\] performance status 0 to 2~* Adequate organ function~Exclusion Criteria:~* Patients with active CNS disease~* Patient with active malignancy with the exception of basal cell carcinoma, non melanoma skin cancer, carcinoma in situ cervical~* Patient has an active, life threatening or clinically significant uncontrolled systemic infection

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy Cohort (Type: EXPERIMENTAL): PF-04449913 Monotherapy
- Combination Cohort 1 (Type: EXPERIMENTAL): PF-04449913 in combination with low dose ARA-C (LDAC)
- Combination Cohort 2 (Type: EXPERIMENTAL): PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
- Azacitidine Combination Cohort (Type: EXPERIMENTAL): PF-04449913 in combination with azacitidine
- Continuation Cohort (Type: EXPERIMENTAL): PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
- Expansion Cohort of LDAC Combination for Efficacy (Type: EXPERIMENTAL): PF-04449913 in combination with LDAC to evaluate efficacy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* The patient has a diagnosis of Bipolar I Disorder and is currently experiencing a major depressive episode.~* The patient is currently being treated with 1 or 2 of the following drugs: lithium, olanzapine, or valproic acid.~Key Exclusion Criteria:~* The patient has any Axis I disorder apart from Bipolar I Disorder that was the primary focus of treatment within 6 months before the screening visit (with the exception of nicotine dependence).~* The patient has any clinically significant uncontrolled medical or surgical condition.~* The patient has previously received modafinil or armodafinil, or the patient has a known sensitivity to any ingredients in the study drug tablets.~* The patient is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Armodafinil (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed local advanced unresectable/metastatic adenocarcinoma of biliary tract~* measurable disease~* available tumor tissue for investigational immunohistochemical evaluations~* ECOG PS 0-2~* No prior chemotherapy, biologic therapy or radiation therapy~* Age Eighteen and older~* Lab values per protocol~Exclusion Criteria:~* Life expectancy less than three months~* Concurrent use of chemotherapy not indicated in the study protocol or any other investigational agents and patients who have received investigational drugs less than four weeks prior to enrollment~* Prior therapy, which affects or targets the EGF pathway~* Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer~* Recovery from major surgery within three weeks of the start of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* women 40 to 60 years~* diagnosis of MDD~* perimenopausal or postmenopausal~Exclusion Criteria:~* using HRT~* using psychotropic medications~* other DSM-IV axis I diagnoses other than MDD

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Current diagnosis of schizophrenia.~* Subject has PANSS total score ≥80, AND score of 4 or more in at least 2 of the following PANSS items at Screening and at Baseline: conceptual disorganization delusions; hallucinatory behavior; unusual thought content.~* Subjects must be able to wear a transdermal patch for 24 hours.~Exclusion Criteria:~* Subject has been diagnosed with schizophrenia less than 6 months prior to Screening Visit.~* Subject has received within 90 days of Screening Visit: electroconvulsive therapy; transcranial magnetic stimulation; vagal nerve stimulation; or other brain stimulation treatments~* Subject has experienced acute depressive symptoms within 30 days prior to Screening Visit that requires treatment with an antidepressant, as determined by the Investigator.~* Currently taking clozapine for the treatment of schizophrenia.~* Has hypothyroidism or hyperthyroidism.~* Subject is currently being treated with insulin for diabetes.~* Subject has epilepsy or history of seizures.~* Positive urine pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose Asenapine maleate patch (Type: EXPERIMENTAL): Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
- High dose asenapine maleate patch (Type: EXPERIMENTAL): High dose asenapine maleate, transdermal patches will be compared against placebo patches.
- Placebo transdermal patch (Type: PLACEBO_COMPARATOR): Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male~* ≥18 to ≤45 years old~* Body mass index (BMI) between 18-30 kg/m² inclusive~* Written informed consent to participate.~Main Exclusion Criteria:~* Any clinically relevant acute or chronic diseases~* Any history of drug or alcohol abuse~* Any History of clinical significant disease as determined by medical history, physical examination or other evaluations.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- MOTREM 1 (Type: EXPERIMENTAL): None
- MOTREM 2 (Type: EXPERIMENTAL): None
- MOTREM 3 (Type: EXPERIMENTAL): None
- MOTREM 4 (Type: EXPERIMENTAL): None
- MOTREM 5 (Type: EXPERIMENTAL): None
- MOTREM 6 (Type: EXPERIMENTAL): None
- MOTREM 7 (Type: EXPERIMENTAL): None
- MOTREM 8 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients;~* Age \> 18 years;~* Type 2 diabetes patients on low or high sodium diet and stable RAS inhibitor therapy with the following conditions:~Urinary albumin excretion (UAE) rate \>300mg/24 hours (200 mcg/min); Serum creatinine \<2 mg/dL, PTH ≥ 20 mEq/L and \<110 mEq/L; Calcium and phosphorus levels \< 9.5 mg/dl and \< 5mg/dl, respectively; Controlled BP (systolic/diastolic \<140/90 mmHg) while on stable RAS inhibitor therapy;~- Written informed consent.~Exclusion Criteria:~* Previous Vitamin D or Vitamin D analogs therapy (within 3 months prior to the study entry);~* Evidence of toxicity to Vitamin D;~* History of kidney stones;~* Poorly controlled Diabetes: Hb1Ac \> 12%;~* Therapy with calcitonin, bisphosphonates, cinacalcet, glucocorticoids, immunosuppressive drugs or other drug that may affect calcium or bone metabolism;~* Cancer and any severe systemic disease or clinical condition that may jeopardize data interpretation or completion of the study;~* Any clinically relevant conditions that might affect study participation and/or study results;~* Any contraindication to be exposed to Paricalcitol;~* Pregnancy or lactating;~* Women of childbearing potential without following a scientifically accepted form of contraception;~* Legal incapacity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Paricalcitol (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years or older as well as willing and able to provide informed consent~* Patients must be undergoing a scheduled surgery for pelvic organ prolapse or urinary incontinence~* Standard postoperative plan must include admission to the hospital with foley catheterization overnight the night after surgery, and planned removal of foley catheter and active voiding trial on postoperative day 1.~Exclusion Criteria:~* Patient unable or unwilling to provide informed consent~* Severe allergy to sulfa drugs~* Known allergy to tamsulosin or another alpha antagonist medication~* History of urinary retention~* Planned bladder catheterization greater than 24 hours after surgery~* Current use of alpha antagonist medication for hypertension~* End stage renal or liver disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Tamsulosin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed solid malignancy that is metastatic or unresectable for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective.~* Subjects with brain metastases must have clinically controlled neurologic symptoms.~* Subject is able to swallow and retain oral medications and does not have uncontrolled emesis.~* Subject has adequate bone marrow, renal and hepatic function per local laboratory reference ranges.~Exclusion Criteria:~* Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2 hyponatremia or hypernatremia.~* Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.~* Subject has a history of cardiac conduction abnormalities.~* Subject has a significant history of cardiovascular disease.~* Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug, or has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy.~* Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7 days prior to the first study dose.~* Use of tobacco or nicotine-containing products within 12 hours prior to the first study dose.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Sequence Group A (Type: EXPERIMENTAL): 200 mg Veliparib
- Sequence Group B (Type: EXPERIMENTAL): 400 mg Veliparib
- Sequence Group C (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children (1-17) and adults (18-75 years old);~* Relapsed or refractory adult and pediatric B-cell precursor ALL after HSCT;~* Evidence of CD19 tumor expression in bone marrow and/or peripheral blood by flow cytometry;~* Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening;~* No evidence of overall aGVHD \> Grade I or chronic GVHD (cGVHD) greater than mild at time of enrollment and in the previous 30 days;~* No longer taking immunosuppressive agents for at least 30 days prior to enrollment;~Exclusion Criteria:~* Patients with GVHD Grades II-IV;~* Any cell therapy in the last 30 days;

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CARCIK-CD19 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Efficacy and Safety of VVZ-149 Injections for Postoperative Pain Following Laparoscopic Colectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women who are at least 18 years of age~* Female subjects who are not pregnant or breastfeeding~* Subjects undergoing a planned first laparoscopic colectomy~* Subjects classified in American Society of Anesthesiologists (ASA) risk class of I or II~* Subjects who report the pain intensity ≥ 5 on the NRS measured after surgery~* Subjects who have the ability to understand study procedures and communicate clearly with the investigator and staff~* Subjects who provide written informed consent prior to participation in the study~Key Exclusion Criteria:~* Subjects undergoing emergency or unplanned surgery~* Subjects who had a previous laparoscopic colectomy procedure, or who had any laparoscopic resection procedure~* Subjects with pre-existing conditions causing preoperative pain at the site of surgery~* Female subjects who are pregnant or breastfeeding~* Diagnosis of chronic pain (e.g., persistent pain with the intensity of NRS ≥ 5 at baseline)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VVZ-149 Injections (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at risk of esophageal squamous cell cancer including those over 50 years old, or over 45 years old with family history of esophageal squamous cell cancer;~* Patients with suspected esophageal lesions by screening endoscopy;~* Patients requiring surveillance after endoscopic resection or radiotherapy for esophageal squamous cell cancer one year later。~Exclusion Criteria:~* Patients allergic to iodine or with hyperthyroidism;~* Patients with advanced esophageal cancer, esophageal varices, esophageal ulcer or other conditions inadvisable for Lugol chromoendoscopy;~* Patients with severe gastroesophageal reflux disease or reflux symptoms which may interfered with the outcome measures of current study;~* Patients with postoperative esophageal stenosis affecting endoscopic observation;~* Patients with serious comorbidities that cannot tolerate un-sedated gastroscopy;~* Patients who could not cooperate with the observation including patients with mental disorders, severe neurosis or dysgnosia;~* Patients undergoing sedation or general anesthesia during endoscopy.~* Patients who do not agree to sign informed consent forms or follow the trial requirement.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- sodium thiosulfate solution arm (Type: ACTIVE_COMPARATOR): 20ml of 5% sodium thiosulfate solution were prepared with 1g sodium thiosulfate crystal dissolved in normal saline in a 20 ml syringe
- N-acetylcysteine solution arm (Type: EXPERIMENTAL): 20ml of 3% N-acetylcysteine solution were prepared with one piece of N-acetylcysteine effervescent tablet （ net weight 0.6g ）dissolved in normal saline in a 20 ml syringe

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 2-11 years of age, nasal obstruction for 3 months, adenoids hypertrophy \> 50% of posterior choanae.~Exclusion Criteria:~* adenoids hypertrophy \< 50% of posterior choanae~recurrent epistaxis or immunodeficiency, severe septal deviation, kissing tonsils, choanal atresia, large masses, known allergy to nasonex (mometasone furoate nasal spray), chronic otitis media, cystic fibrosis, acute infection.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- mometasone furoate nasal spray (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete